The Healthcare Policy Podcast ®  Produced by David Introcaso
The Healthcare Policy Podcast ® Produced by David Introcaso
Ms. Priti Krishtel Discusses the Biden Administration's Support for a Temporary WTO COVID-19 Vaccine Patent Waiver (June 10th)

Ms. Priti Krishtel Discusses the Biden Administration's Support for a Temporary WTO COVID-19 Vaccine Patent Waiver (June 10th)

Last October India and South Africa appealed to the World Trade Organization to temporarily waive patent or intellectual property (IP) rights such that COVID-19 production and distribution worldwide could be accelerated.   As of a month ago 80% of COVID-19 vaccines had gone to those in in high or upper middle income countries while only 0.2% had gone to those in low income countries - meaning it was projected to take until 2024 to inoculate developing world populations.  The Trump administration opposed a waiver.  In early May, the Biden administration announced it would support a so called TRIPS (Trade-Related Aspects of Intellectual Property Rights) waiver over the opposition the European Union (EU) and the pharmaceutical industry - though Moderna announce last fall it would not enforce its COVID vaccine-related patents).   Along with recent administration announcements to purchase and distribute over 500 million vaccines worldwide, the administration has evidently recognized the moral imperative and the fact COVAX, the WTO's initiative to pool vaccine resources, remains profoundly underfunded.      

During this 26 minute conversation Ms. Krishtel moreover explains why the Biden administration was unprecedented, the definition of a waiver, its timing and the practical issue of tech transfer.  She goes on to address or refute the industry's objections to a temporary waiver and discusses more generally inherent problems with the market-driven US patent system.  Among other issues, it undermines the purpose of public investment, socializes risk while privatizing profits (or places profits over people) and slows the worldwide diffusion of pharmaceutical know how.         

Ms. Priti Krishtel is the co-founder of Initiatives for Medicines Access and Knowledge (I-MAK),  a non-profit building a more just and equitable medicines system.  She has spent nearly two decades exposing structural inequities affecting access to medicines and vaccines moreover across the Global South.  Of late this work includes advocating for equitable access to COVID-19 vaccines across the globe and helping to ensure the Biden administration prioritizes equity the US Patent and Trademark Office's work.  I-MAK's work on the patent system has been cited repeatedly in Congressional testimony on prescription drug costs, most recently in hearings by the House Committee on Oversight and Reform.   To improve equity in the patent system, I-MAK recently developed a new tool called Participatory Changemaking that will provide an assessment of the patent system and bring together stakeholders from across the stakeholder spectrum, from patients to investors and policymakers, to drive sustainable, long-term change into what has long been an exclusionary process.  Ms. Krishtel and I-MAK have also put out a 10 point plan for the Biden administration to bring equity into the patent system.  She is a recent TED speaker, Presidential Leadership Scholar, and an Ashoka Fellow.

For information on I-MAK go to:   

Ms. Krishtel's recent British Medical Journal article noted during this discussion is at:

The Ink interview noted during this interview is at:

The Healthcare Policy Podcast ®  Produced by David Introcaso
The Healthcare Policy Podcast ® Produced by David Introcaso
Podcast interviews with health policy experts on timely subjects.
The Healthcare Policy Podcast website features audio interviews with healthcare policy experts on timely topics.
An online public forum routinely presenting expert healthcare policy analysis and comment is lacking. While other healthcare policy website programming exists, these typically present vested interest viewpoints or do not combine informed policy analysis with political insight or acumen. Since healthcare policy issues are typically complex, clear, reasoned, dispassionate discussion is required. These podcasts will attempt to fill this void.
Among other topics this podcast will address:
Implementation of the Affordable Care Act
Other federal Medicare and state Medicaid health care issues
Federal health care regulatory oversight, moreover CMS and the FDA
Healthcare research
Private sector healthcare delivery reforms including access, reimbursement and quality issues
Public health issues including the social determinants of health
Listeners are welcomed to share their program comments and suggest programming ideas.
Comments made by the interviewees are strictly their own and do not represent those of their affiliated organization/s.